$1.27
0.086.72%
At close: -
$1.21
-0.06-4.72%
After Hours: 4:23 PM EDT
Comments
Loading...
IGM Biosciences Analyst Ratings and Price Targets | NASDAQ:IGMS | Benzinga
IGM Biosciences Inc has a consensus price target of $10 based on the ratings of 13 analysts. The high is $31 issued by Baird on June 1, 2022. The low is $1.5 issued by RBC Capital on January 10, 2025. The 3 most-recent analyst ratings were released by Jefferies, Truist Securities, and Stifel on January 10, 2025, respectively. With an average price target of $2.17 between Jefferies, Truist Securities, and Stifel, there's an implied 79.06% upside for IGM Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
Truist Securities
Stifel
RBC Capital
BMO Capital
1calculated from analyst ratings
Analyst Ratings for IGM Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/13/2025 | Buy Now | — | JP Morgan | Eric Joseph43% | — | Upgrade | Underweight → Neutral | Get Alert |
| 01/10/2025 | Buy Now | 65.29% | Jefferies | Roger Song30% | $48 → $2 | Downgrade | Buy → Hold | Get Alert |
| 01/10/2025 | Buy Now | 65.29% | Truist Securities | Asthika Goonewardene40% | $12 → $2 | Maintains | Hold | Get Alert |
| 01/10/2025 | Buy Now | 106.61% | Stifel | Stephen Willey49% | $27 → $2.5 | Downgrade | Buy → Hold | Get Alert |
| 01/10/2025 | Buy Now | 23.97% | RBC Capital | Brian Abrahams47% | $20 → $1.5 | Downgrade | Outperform → Sector Perform | Get Alert |
| 01/10/2025 | Buy Now | 65.29% | BMO Capital | Etzer Darout44% | $21 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/06/2024 | Buy Now | 1635.54% | BMO Capital | Etzer Darout44% | → $21 | Initiates | → Outperform | Get Alert |
| 11/11/2024 | Buy Now | 2131.4% | Stifel | Stephen Willey49% | $25 → $27 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 1552.89% | RBC Capital | Brian Abrahams47% | $17 → $20 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 1552.89% | Guggenheim | — | $25 → $20 | Maintains | Buy | Get Alert |
| 10/01/2024 | Buy Now | 1718.18% | Wedbush | Robert Driscoll43% | $25 → $22 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 1304.96% | RBC Capital | Brian Abrahams47% | $20 → $17 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 643.8% | JP Morgan | Eric Joseph43% | $12 → $9 | Downgrade | Neutral → Underweight | Get Alert |
| 10/01/2024 | Buy Now | 891.74% | Truist Securities | Asthika Goonewardene40% | $24 → $12 | Downgrade | Buy → Hold | Get Alert |
| 09/05/2024 | Buy Now | 809.09% | HC Wainwright & Co. | Robert Burns41% | $12 → $11 | Maintains | Neutral | Get Alert |
| 08/23/2024 | Buy Now | 1883.47% | Truist Securities | Asthika Goonewardene40% | $25 → $24 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | 1966.12% | Wedbush | Robert Driscoll43% | $20 → $25 | Maintains | Outperform | Get Alert |
| 08/15/2024 | Buy Now | 1552.89% | RBC Capital | Brian Abrahams47% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 891.74% | JP Morgan | Eric Joseph43% | $11 → $12 | Maintains | Neutral | Get Alert |
| 05/24/2024 | Buy Now | 891.74% | HC Wainwright & Co. | Robert Burns41% | $12 → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 1552.89% | Wedbush | Robert Driscoll43% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 04/18/2024 | Buy Now | 891.74% | HC Wainwright & Co. | Robert Burns41% | → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 891.74% | HC Wainwright & Co. | Robert Burns41% | $7 → $12 | Maintains | Neutral | Get Alert |
| 03/08/2024 | Buy Now | 1552.89% | Wedbush | Robert Driscoll43% | $20 → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 1635.54% | RBC Capital | Brian Abrahams47% | $21 → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 02/09/2024 | Buy Now | 1635.54% | RBC Capital | Brian Abrahams47% | $9 → $21 | Upgrade | Sector Perform → Outperform | Get Alert |
| 12/15/2023 | Buy Now | 561.16% | B of A Securities | Geoff Meacham60% | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 12/07/2023 | Buy Now | 478.51% | HC Wainwright & Co. | Robert Burns41% | $11 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2023 | Buy Now | 891.74% | JP Morgan | Eric Joseph43% | $15 → $12 | Maintains | Neutral | Get Alert |
| 12/06/2023 | Buy Now | 643.8% | RBC Capital | Brian Abrahams47% | $8 → $9 | Maintains | Sector Perform | Get Alert |
| 11/15/2023 | Buy Now | 561.16% | Morgan Stanley | Michael Lapides62% | $15 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | 809.09% | HC Wainwright & Co. | Robert Burns41% | $17 → $11 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 1966.12% | Stifel | Stephen Willey49% | $26 → $25 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 561.16% | RBC Capital | Brian Abrahams47% | $11 → $8 | Maintains | Sector Perform | Get Alert |
| 09/06/2023 | Buy Now | 1966.12% | Truist Securities | Asthika Goonewardene40% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | 809.09% | RBC Capital | Brian Abrahams47% | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/07/2023 | Buy Now | — | Needham | Matt McGinley73% | — | Downgrade | Buy → Hold | Get Alert |
| 08/07/2023 | Buy Now | 1304.96% | HC Wainwright & Co. | Robert Burns41% | $22 → $17 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 1139.67% | Morgan Stanley | Michael Lapides62% | $20 → $15 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 1139.67% | JP Morgan | Eric Joseph43% | $19 → $15 | Maintains | Neutral | Get Alert |
| 06/06/2023 | Buy Now | 1718.18% | HC Wainwright & Co. | Robert Burns41% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 2957.85% | Wedbush | Robert Driscoll43% | → $37 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | 1470.25% | JP Morgan | Eric Joseph43% | $26 → $19 | Maintains | Neutral | Get Alert |
| 05/15/2023 | Buy Now | 2957.85% | Wedbush | Robert Driscoll43% | $41 → $37 | Maintains | Outperform | Get Alert |
| 05/15/2023 | Buy Now | 1304.96% | RBC Capital | Brian Abrahams47% | $21 → $17 | Maintains | Sector Perform | Get Alert |
| 04/04/2023 | Buy Now | 1966.12% | Truist Securities | Asthika Goonewardene40% | $37 → $25 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 2048.76% | JP Morgan | Eric Joseph43% | $27 → $26 | Maintains | Neutral | Get Alert |
| 04/03/2023 | Buy Now | 1552.89% | Morgan Stanley | Michael Lapides62% | $30 → $20 | Maintains | Equal-Weight | Get Alert |
| 04/03/2023 | Buy Now | 1718.18% | HC Wainwright & Co. | Robert Burns41% | $45 → $22 | Maintains | Buy | Get Alert |
| 03/31/2023 | Buy Now | 1635.54% | RBC Capital | Brian Abrahams47% | $24 → $21 | Maintains | Sector Perform | Get Alert |
| 11/09/2022 | Buy Now | 4445.45% | Jefferies | Roger Song30% | $61 → $55 | Assumes | → Buy | Get Alert |
| 11/07/2022 | Buy Now | 3619.01% | HC Wainwright & Co. | Robert Burns41% | $58 → $45 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 1718.18% | RBC Capital | Brian Abrahams47% | $27 → $22 | Maintains | Sector Perform | Get Alert |
| 10/17/2022 | Buy Now | 2131.4% | JP Morgan | Eric Joseph43% | → $27 | Initiates | → Neutral | Get Alert |
| 08/29/2022 | Buy Now | 2709.92% | B of A Securities | Geoff Meacham60% | → $34 | Initiates | → Buy | Get Alert |
| 08/23/2022 | Buy Now | 2957.85% | Truist Securities | Asthika Goonewardene40% | $74 → $37 | Maintains | Buy | Get Alert |
| 06/01/2022 | Buy Now | 2461.98% | Baird | Joel Beatty63% | $46 → $31 | Maintains | Outperform | Get Alert |
| 05/17/2022 | Buy Now | 4693.39% | HC Wainwright & Co. | Robert Burns41% | $59 → $58 | Maintains | Buy | Get Alert |
FAQ
What is the target price for IGM Biosciences (IGMS) stock?
The latest price target for IGM Biosciences (NASDAQ:IGMS) was reported by JP Morgan on January 13, 2025. The analyst firm set a price target for $0.00 expecting IGMS to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IGM Biosciences (IGMS)?
The latest analyst rating for IGM Biosciences (NASDAQ:IGMS) was provided by JP Morgan, and IGM Biosciences upgraded their neutral rating.
When was the last upgrade for IGM Biosciences (IGMS)?
The last upgrade for IGM Biosciences Inc happened on January 13, 2025 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for IGM Biosciences Inc.
When was the last downgrade for IGM Biosciences (IGMS)?
The last downgrade for IGM Biosciences Inc happened on January 10, 2025 when Jefferies changed their price target from $48 to $2 for IGM Biosciences Inc.
When is the next analyst rating going to be posted or updated for IGM Biosciences (IGMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.
Is the Analyst Rating IGM Biosciences (IGMS) correct?
While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a upgraded with a price target of $0.00 to $0.00. The current price IGM Biosciences (IGMS) is trading at is $1.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.